We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,706.00
Bid: 1,706.00
Ask: 1,706.50
Change: 33.00 (1.97%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,706.50
Low: 1,673.00
Prev. Close: 1,673.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Fresnillo Falls While Housebuilders, GSK Rise

Wed, 25th Jul 2018 11:59

LONDON (Alliance News) - Stocks continued to trade mostly lower at midday on Wednesday, with focus on a meeting between the European Commission president and US president amid escalating global trade tensions."It will be interesting to see if anything can be achieved during Jean-Claude Junckers visit to Washington today, with the European Commission president hoping to convince [Donald] Trump to drop plans to impose tariffs on the EU, something I am not hopeful he will be able to achieve," commented Oanda senior market analyst Craig Erlam.Holding back the FTSE 100 were losses for Fresnillo and Informa, with housebuilders and GlaxoSmithKline among blue-chips gaining.The FTSE 100 was down 0.6%, or 47.71 points, at 7,661.34 Wednesday midday. The mid-cap FTSE 250 index was down 0.2%, or 46.20 points, at 20,806.67. The AIM All-Share index was up 0.3% at 1,097.41.The Cboe UK 100 was down 0.8% at 12,985.12, the Cboe UK 250 was down 0.2% at 18,952.04, while the Cboe UK Small Companies was flat at 12,389.46.In UK data, mortgage approvals rose to a nine-month high in June of 40,541 from 39,528 in May. Gross mortgage lending grew 2.1% on year to GBP23.5 billion in June. Meanwhile, credit card spending was 4.7% higher than a year earlier. "Card spending saw relatively strong growth year on year, with retail sales buoyed by the sunshine and recent sporting events," Eric Leenders, managing director, personal finance at UK Finance said."Meanwhile growth in mortgage lending continues to be driven by remortgaging, as borrowers take advantage of attractive deals ahead of an anticipated Bank rate rise," Leenders added. The Bank of England announces its latest monetary policy decision on August 2.In Germany, business sentiment weakened marginally in July as survey results from Ifo Institute showed its business confidence index fell to 101.7 from 101.8 in June. This was, nonetheless, slightly improved on the expected fall to 101.5.In mainland Europe on Wednesday, the CAC 40 in Paris was up 0.1% while the DAX 30 in Frankfurt was down 0.2% at midday.European Commission President Juncker is in Washington on Wednesday for a White House meeting with Trump, a day after the US president called the EU a "big abuser" of trade relations.Trump last month slapped tariffs on steel and aluminium from the EU, which responded with hiked import taxes on USD3 billion worth of US goods - politically targeted products ranging from peanut butter to whiskey and motorcycles.The US president tweeted late Tuesday that the EU should "drop all tariffs, barriers and subsidies"."That would finally be called Free Market and Fair Trade! Hope they do it, we are ready - but they won't!" the president wrote in his social media post.The Europe-US meeting also comes after the International Monetary Fund said Tuesday that Trump's protectionist tariffs are unlikely to shrink US trade deficits. The US government budget deficit - now on course to top USD1 trillion a year - is causing a stronger dollar and actually fuelling US trade deficits, the IMF said.Markets in the US are called to open largely flat on Wednesday as investors eye a packed earnings session. The Dow Jones and Nasdaq are called flat, with the S&P 500 to decline 0.1%.Aerospace firm Boeing, soft drinks maker Coca-Cola and car manufacturer General Motors report before the market opens, with payment services provider Visa, semiconductor designer Qualcomm, social media network Facebook, and Ford Motor reporting after the market closes.Sergio Marchionne, the former head of Italian-American carmaker Fiat-Chrysler Automobiles, who stepped down Saturday due to ill health, has died aged 66, his former company said on Wednesday. In a statement, FCA Chairman John Elkann, said: "Unfortunately, what we feared has come to pass. Sergio Marchionne, man and friend, is gone."In the economic calendar, US new homes sales are due at 1500 BST and EIA crude oil stocks at 1530 BST.Released just before midday, GlaxoSmithKline was up 1.6% in London after it reported a jump in interim profit, upgraded its annual guidance, and also unveiled a four-year collaboration with consumer genetics research company 23andMe.Glaxo said second quarter sales totalled GBP7.3 billion, flat at actual exchange rates but up 4% at constant currencies. For the first half of the year, sales fell 1.1% to GBP14.53 billion from GBP14.70 billion, but pretax profit climbed 26% to GBP1.72 billion from GBP1.37 billion.The drugmaker declared a dividend of 19p for the quarter, continuing to target an 80p payout for the year.Following an "encouraging" first half, Glaxo upgraded its guidance, expecting annual adjusted earnings per share growth between 7% to 10% at constant exchange rates if there is no generic competitor to Advair introduced to the US. If a generic is introduced, EPS is expected to grow in a range of 4% to 7%.In addition, Glaxo said a new "major restructuring" programme is expected to deliver annual costs savings of GBP400 million by 2021.Separately, Glaxo said a collaboration with 23andMe is expected to identify novel drug targets, tackle new subsets of disease and enable" rapid progression" of clinical programmes.All activities within the collaboration will initially be co-funded equally, and Glaxo has made a USD300 million investment in the California-based company.At the top of the FTSE 100 was 3i Group, up 3.1% after the private equity investor said it made a "good start" to the year. Net asset value per share stood at 760 pence at June 30, up 5.0% from 724p at March 31.Taylor Wimpey gained 1.5%, with Barratt Developments rising 1.2%, after Berenberg initiated both housebuilders with a Buy rating.At the bottom of the blue-chip list was Fresnillo, down 5.7% as the miner lowered its annual silver production guidance, though it did raise its expectations for gold.Silver production in the second quarter of the year was up 5.7% on year, whilst production over the first six months of 2018 was up 9.7% to 30.8 million ounces. Gold production in the second quarter was up 4.6%, up 4.4% over the half to 465,000 ounces.Looking to 2018 as a whole, Fresnillo sees total gold production between 900,000 ounces to 930,000 ounces - previously guided between 870,000 ounces and 900,000 ounces - while silver is seen slightly lower, between 64.5 million ounces to 67.5 million ounces, from the previously guided 67 million ounces to 70 million ounces.Informa was 3.7% lower after the events and business information group reported a decrease in profit for the first half of 2018, hit by costs related to its takeover of peer UBM.For the six months ended June 30, the company reported pretax profit of GBP120.3 million, down 19% from GBP148.6 million for the same period a year before, despite revenue growing 4.6% to GBP957.1 million. Informa booked GBP52.2 million in acquisition & integration costs during the period.In the FTSE 250, Indivior slumped 15% after the drugmaker reported a drop in half year earnings, with no new guidance to replace that which it withdrew earlier this month due to the brief market entry of Indian rival Dr Reddy's Laboratories generic buprenorphine/naloxone sublingual film. The company posted a fall in net revenue, down 5% to USD524 million from USD553 million a year ago. Operating profit dropped to USD200 million from USD244 million.Brewin Dolphin was the biggest mid-cap gainer, up 6.2% after the investment manager said total funds increased in the third quarter. In the three months ended June 30, Brewin Dolphin total funds increased 6.6% to GBP42.3 billion from GBP39.7 billion at the end of the previous quarter.On London's junior AIM market, Burford Capital climbed 11% after the arbitration and litigation finance provider reported a 14% rise in interim pretax profit to USD164.6 million, with total income up 17% to USD205.2 million.
More News
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.